FIRST Faculty

Open Position


+49 (0) 69/798-29801



NATIONAL networks



FIRST faculty members coordinate and/or participate in a number of regional, national and international scientific networks which are also dedicated to training excellent PhD students.




German Research Network of Neuropathic Pain (GNNP)

The GNNP funded by the BMBF(01EM0511) includes all major German experimental and clinical institutions, authorities and medical disciplines engaged in research and therapy on neuropathic pain. Using a translational approach the networks aim to i) define pathophysiological mechanisms of neuropathic pain, ii) introduce innovative interventions to prevent and treat pain iii) establish a data base of patients including psychological, quantitative sensory and genetic (single nucleotide polymorphisms) information.

Research Unit (Krebshilfe-Forschergruppe)

The integrated scientific research group entitled "Pathological gene products and disease mechanisms" was established in 2005 and has an emphasis on the pathological disease mechanisms of acute leukemias and Hodgkin lymphomas. The long-term aim of the integrated research group is the development of novel therapeutic strategies that allow us to interfere with these specific cancer types. Within the consortium several experimental platforms have been established to integrate and disseminate excellence in topics such as vector construction, retroviral transduction of pathological fusion genes, gene expression profiling, cell based-assays, proteininteractions and establishment of standardized animal model systems. Graduate and post-graduate education takes the form of seminars (teaching modules in cancer biology, cancer development and treatment, molecular medicine) and retreats. Practical education for graduate students is enhanced by visiting and working in different laboratories of the consortium, to foster optimal education and dissemination of technical skills.

CancerNet within the
National Genome Research Network (NGFN)

The Georg-Speyer-Haus (GSH) and several project leaders of Division III participate in CancerNet within the National Genome Research Network (NGFN), which is the most comprehensive instrument engaged in interdisciplinary disease-oriented genomic research in Germany.

TreatID (BMBF)

The BMBF-funded research network ‘Treatment of severe immunodeficiencies with gene-modified stem cells "TreatID" has strong links to Division III and IV. Treatment of severe immunodeficiencies with gene-modified hematopoietic stem cells (HSC) is the only gene therapeutic strategy to date that has proven to be highly effective in humans. Within TreatID, severe immunodeficiencies are treated with gene-modified HSC in phase I/II clinical trials. These include: AIDS-related lymphoma, severe manifestations of the congenital immunodeficiencies chronic granulomatous disease and Wiskott-Aldrich syndrome. Associated research groups will improve the safety of viral gene transfer vectors to allow the treatment of patients with less severe disease manifestations. The network is coordinated by the Georg-Speyer-Haus.


Collaborative Research Centre SFB/TR23 Vascular differentiation and remodeling

Vascular diseases are directly or indirectly linked to diseases such as hypertension, myocardial infarction, stroke, cancer but also to diabetes and obesity. The investigation of the molecular and cellular mechanisms affecting the vascular system, particular the vessel wall, during the development of the disease, are the focus of the SFB/TR23. Researchers from the following institutions are participating in the SFB/TR23: University Hospital Frankfurt/Main, University Hospital Heidelberg, Faculty for Clinical Medicine, Mannheim, DKFZ Heidelberg, University ofFreiburg, Tumor Biology Center, Freiburg.